Treatment Adverse Events Vary With Favorable, Unfavorable Prognosis in Prostate Cancer
By Elana Gotkine HealthDay Reporter
MONDAY, Jan. 29, 2024 -- For patients with localized prostate cancer, the rates of adverse outcomes associated with specific treatments vary for favorable- and unfavorable-prognosis disease, according to a study published online in the Jan. 23/30 issue of the Journal of the American Medical Association.
Bashir Al Hussein Al Awamlh, M.D., from Vanderbilt University Medical Center in Nashville, Tennessee, and colleagues conducted an observational cohort study using data from five U.S. Surveillance, Epidemiology, and End Results Program registries to compare rates of adverse functional outcomes between specific treatments for localized prostate cancer. At baseline, 1,877 and 568 participants had favorable- and unfavorable-prognosis prostate cancer. Treatment included radical prostatectomy, external beam radiotherapy, brachytherapy, or active surveillance for favorable-prognosis disease (1,043, 359, 96, and 379, respectively) and radical prostatectomy or external beam radiotherapy with androgen deprivation therapy for unfavorable-prognosis disease (362 and 206, respectively). Patients were followed for a median of 9.5 years.
The researchers found that compared with active surveillance, radical prostatectomy was associated with worse urinary incontinence but not sexual function among men with a favorable prognosis. Among those with an unfavorable prognosis, radical prostatectomy was associated with worse urinary incontinence but not sexual function compared with external beam radiotherapy with androgen deprivation therapy. Worse bowel and hormone function were seen for those with an unfavorable prognosis receiving external beam radiotherapy with androgen deprivation therapy compared with radical prostatectomy.
"In this observational study of patients with localized prostate cancer followed up for approximately 10 years, functional outcomes varied by treatment and prognosis at the time of diagnosis," the authors write.
Several authors disclosed ties to the biopharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted January 2024
Read this next
Lesbian, Bisexual Women Face Premature Death Versus Heterosexual Women
TUESDAY, May 7, 2024 -- Female nurses identifying as lesbian or bisexual have markedly earlier mortality than heterosexual nurses, according to a study published online April 25...
Plant-Based Diet May Aid Prostate Cancer Outcomes
FRIDAY, May 3, 2024 -- Consuming a primarily plant-based diet may be associated with better cancer-specific health outcomes among men with prostate cancer, according to a study...
Neoadjuvant Chemohormonal Therapy Aids Locally Advanced Prostate Cancer
THURSDAY, May 2, 2024 -- For patients with locally advanced prostate cancer, neoadjuvant chemohormonal therapy (NCHT) is beneficial for biochemical progression-free survival...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.